Figure 3 Adverse cardiovascular consequences of synthetic cannabinoids

Slides:

Advertisements

Similar presentations

Nat. Rev. Cardiol. doi: /nrcardio

Advertisements

Figure 2 Electromechanical properties of OIHPs

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Metabolism pathway of antiplatelet agents

Figure 5 BMI and cardiorespiratory fitness levels

Figure 8 Implanted devices for the management of heart failure

Figure 4 Pharmacodynamic comparison of crushed versus integral

Figure 1 Cine cardiovascular magnetic resonance (CMR)

Figure 3 T1 mapping and late gadolinium enhancement (LGE)

Figure 4 BMI and mortality in patients with heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Global rates of sodium, fruit, and vegetable intake

Figure 2 Bad-metal behaviour and electron correlations

Figure 1 Anatomy of the femoral artery

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Three-year survival rates on the basis of body composition

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Figure 3 Lineage tracing of resident cardiac fibroblasts

Nat. Rev. Cardiol. doi: /nrcardio

Figure 6 Pharmacodynamic profile of switching between clopidogrel and ticagrelor therapy: results from the RESPOND study Figure 6| Pharmacodynamic profile.

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Health-care system today

Figure 1 Cardiovascular risk and disease across the life-course

Figure 2 The depolarization theory of Brugada syndrome

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Neural crest cell migration

Figure 2 Global cost of HF per capita in 2012

Figure 2 A patient with aortic stenosis and mitral regurgitation

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Challenges for big data applications in cardiovascular care

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Effects of cardiovascular medication on the fetus

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 5 Bioresorbable vascular scaffold apposition and strut coverage

Figure 6 Combining population-wide and high-risk strategies

Figure 6 Cardiac fibroma

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 12 Cardiac gossypiboma

Figure 6 The neurogenic components of angina

Figure 1 Ventricular end-diastolic pressure–volume relationship curves

MicroRNAs in Memory Processing

Figure 4 Electrocardiogram patterns associated with Brugada syndrome

Figure 1 Platelet receptors and available pharmaceutical options

Nat. Rev. Cardiol. doi: /nrcardio

Shahrokh Javaheri et al. JACC 2017;69:

Figure 2 Impaired mitochondrial capacity and function in heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 4D printing schemes and time-evolving structure geometries

Nat. Rev. Cardiol. doi: /nrcardio

Right ventricular (RV) pressure–volume loops at decreasing venous return in a patient with a) systemic sclerosis-associated pulmonary arterial hypertension.

Figure 2 Diffusio-osmotic process for osmotic energy conversion

Presentation transcript:

Figure 3 Adverse cardiovascular consequences of synthetic cannabinoids Figure 3 | Adverse cardiovascular consequences of synthetic cannabinoids. Cardiovascular effects of potent synthetic cannabinoid receptor 1 (CB1R) agonist HU210. Intravenous administration of HU210 (0.1 mg/kg) to a rat dramatically decreases left ventricular (LV) pressure (blue trace), LV contractility (+dP/dt; green trace), and blood pressure (purple trace), and shifts pressure–volume loops to the right, indicating decreased cardiac performance. After injection of a CB1R antagonist, SR141716 (rimonabant; 10 mg/kg), cardiac function and blood pressure largely recover within 20 mins. Reprinted with permission from Pacher, P. et al. Measurement of cardiac function using pressure–volume conductance catheter technique in mice and rats. Nat. Protoc. 3 (9), 1422–1434 (2008), with permission from Macmillan Publishers Limited. Reprinted with permission from Pacher, P. et al. Measurement of cardiac function using pressure–volume conductance catheter technique in mice and rats. Nat. Protoc. 3 (9), 1422–1434 (2008), with permission from Macmillan Publishers Limited. Pacher, P. et al. (2017) Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.130